Prostate Cancer: The “Silent Threat” That Still Slips Through Primary Care
Introduction
Prostate cancer remains one of the most common cancers seen in men, yet many patients still present late. Despite improvements in PSA testing, MRI pathways, and risk stratification, early detection in primary care continues to be a challenge — especially when most early disease is asymptomatic.
Why This Matters in General Practice
Many men don’t attend until symptoms become disruptive, and even then, they may minimise or normalise urinary changes. As GPs, you’re often the first point of contact — and sometimes the only opportunity for early intervention.
Early-stage prostate cancer is usually silent, so proactive conversations, opportunistic case-finding, and clear safety-netting can make a significant difference.
Key Risk Factors to Keep on Your Radar
Incidence remains highest in North America and Europe, with well-established risk factors including:
- Age – median diagnosis around 66
- Family history – especially first-degree relatives
- African or Caribbean ancestry – higher incidence and mortality
- Genetic predisposition – BRCA1/2 and other inherited mutations
These groups benefit most from earlier discussion and shared decision-making around PSA testing.
Clinical Presentation: What Patients May Report (If Anything)
While many cases are picked up through screening, symptomatic presentations can include:
- Lower urinary tract symptoms (LUTS)
- Hematuria or hematospermia
- Erectile dysfunction
- Bone pain — often indicating metastatic spread
Given the overlap with benign prostatic hyperplasia, symptom context and risk factors are key.
Screening and Early Detection in Primary Care
Current UK practice focuses on informed choice rather than routine screening. Useful tools include:
- PSA testing – still central to early detection
- MRI-first pathways – improving diagnostic accuracy and reducing unnecessary biopsies
- DRE – now considered a poor standalone test by BAUS and Prostate Cancer UK, but may still support clinical assessment in symptomatic patients
Clear communication around PSA limitations, false positives, and follow-up pathways remains essential.
Risk Stratification: What Comes Next
Once diagnosed, patients are categorised into low, intermediate, or high risk based on:
- PSA level
- Gleason score
- Clinical stage
This guides whether patients are suitable for active surveillance or require more definitive treatment
Management Options You’ll Commonly Discuss
Early-stage prostate cancer may be managed with:
- Active surveillance – increasingly common for low-risk disease
- Radical prostatectomy
- Radiotherapy
- Hormone therapy
Primary care plays a crucial role in ongoing monitoring, managing treatment side effects, and supporting long-term survivorship.
If you’d like more information on prostate cancer education or upcoming men’s health events for clinicians, visit our courses on our website, or you can get in touch at info@dovetailhealthevents.com.
